

## Department of Medicine

### COVID-19 Information Bulletins

Week of December 20 – 24, 2021

---

#### COVID UPDATES – DECEMBER 24

Please see the attached memos and documents in regards to COVID-19 Updates:

- **NEW:** [Omicron variant of concern – Updated PPE Recommendations](#) – December 24, 2021
- **NEW:** [Testing and Case Investigation Changes in Response to Omicron Spread –AHS Emergency Coordination Centre](#) – December 23, 2021
- **NEW:** [Break Room Etiquette – ZEOC Memo](#) – December 23, 2021
- **NEW:** [Break Room Checklist](#) – December 23, 2021

Please also continue to check the [Insite COVID-19 Resource page](#) for up to date documents.

---

#### IMPORTANT COVID-19 UPDATES

Please see the attached memo and the below updated treatment guidelines:

- [Current Guidance for the Management of Adult Hospitalized Patients with COVID-19](#)
- [Therapeutic Management of Adult Patients with COVID-19](#)
- [Access changes for designated support persons and visitors at AHS sites](#)

Please also remember to complete your [Fit for Work questionnaire](#) prior to coming to work at an AHS facility.

---

#### UPDATED COVID-19 TREATMENT RECOMMENDATIONS – DECEMBER 22

*Message from Pharmacy Services, Jeremy Slobodan*

The Current Guidance for the Management of Adult Hospitalized Patients with COVID-19 ([found here](#)) and one Page Treatment summary ([found here](#)) have been approved by ECC and are updated and posted online, after review by the COVID-19 Therapeutics Working Group.

In addition, an update has been made to the attached FAQ to support clinicians with the use of drugs related to the treatment of COVID-19 patients (attached and linked on the formulary page of the key drugs). If there are questions not addressed that you would like answered, please submit them to [AHS.PharmacyTherapeuticsDUS@albertahealthservices.ca](mailto:AHS.PharmacyTherapeuticsDUS@albertahealthservices.ca) and we will consider your question in a future update or respond directly to you.

The main updates are as follows:

### 1. Casirivimab-imdevimab (Ronapreve® formerly known as REGEN-COV®)

As casirivimab-imdevimab fails to neutralize the Omicron variant in *in vitro* assays<sup>11,12</sup>, if a patient is infected with a confirmed or suspected Omicron variant, casirivimab-imdevimab should not be used.

### 2. Sotrovimab

Updated to include sotrovimab for inpatients for nosocomial infections and for patients admitted for non-COVID reasons.

For inpatient use:

- It is not for use in patients hospitalized due to COVID-19
- It can be ordered by the attending physician. Access for inpatients does not need to be approved through outpatient process (i.e. contacting Health Link)

Please share this information with your colleagues as applicable.

- [Drug Treatments for COVID-19 FAQ](#)

---

Communications Team

Department of Medicine

Alberta Health Services – Calgary Zone and Cumming School of Medicine, University of Calgary

9<sup>th</sup> Floor, North Tower, FMC, 1403 - 29th Street NW, Calgary, AB, T2N 2T9

E: [dom.announcements@ahs.ca](mailto:dom.announcements@ahs.ca) | W: [departmentofmedicine.com](http://departmentofmedicine.com)